# A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

> **NCT00816400** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 49 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** MEDI-575

## Key facts

- **NCT ID:** NCT00816400
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-02
- **Primary completion:** 2012-01-19
- **Final completion:** 2012-01-19
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00816400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00816400, "A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00816400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*